🟢 First Tracks Biotherapeutics is trading 5% up today after Guggenheim's Buy rating and $100 target

First Tracks Biotherapeutics is trading at $40.40, up +5.02%, after Guggenheim initiated coverage on September 16, 2026, with a Buy rating and a $100 price target.

• The company is also participating in the Morgan Stanley Global Healthcare Conference on September 16, supporting investor attention.
• The gain appears company-specific because biotech-sector sentiment is negative while First Tracks Biotherapeutics moves higher.